ADC Therapeutics SA (ADCT)
Last updated: 2026-10-20 23:07:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
ADC Therapeutics SA (ADCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1.53, with a market capitalization of $178.73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.78 to $4.98. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$178.73M | |
$1.45 | |
$56.59 | |
$0.36 | |
$1.44 | |
959.06K | |
1.54M | |
-- | |
$4.98 | |
$0.78 | |
-- | |
-- |
ADC Therapeutics SA (ADCT) After-Hours Stock Price
ADC Therapeutics SA (ADCT) is trading at $1.53 in after-hours trading as of 2026-10-20 22:48:49, up 5.90% ($0.08) from the regular-session close of $1.44.
After-hours trading shows how investors are pricing ADCT after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
ADC Therapeutics SA (ADCT) 7-Day Stock Price Change
Over the past seven days, ADC Therapeutics SA (ADCT) moved from $1.73 to $1.53, representing a decline of 11.85% ($0.21).
The stock traded between $1.39 and $1.87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.79 million shares, down versus the previous seven-day period, indicating lower trading activity.
ADCT 52-Week Price Position
Position in Range: 17.7%
ADCT is currently trading at $1.53, placing it 17.7% of the way from its 52-week low of $0.78 to its 52-week high of $4.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is ADC Therapeutics SA (ADCT)?
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
ADC Therapeutics SA Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 193 |
| Exchange | NYSE |
| Company Website |
How to Buy ADC Therapeutics SA (ADCT) Stock on MEXC
Eligible investors can buy real shares of ADC Therapeutics SA (ADCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is ADC Therapeutics SA (ADCT) stock price today?
2.Is ADCT stock going up or down today?
3.What is ADCT pre-market price?
4.What is ADCT after-hours price?
5.Is ADCT stock trading now?
6.Where does ADCT sit relative to its 52-week high and low?
7.What sector is ADC Therapeutics SA in?
8.What is ADC Therapeutics SA's market capitalization and where is it listed?
9.How is ADCT valued in terms of P/E ratio and EPS?
10.Does ADC Therapeutics SA pay a dividend?
Explore More US Stocks
Search Stocks
ADCT Stock Calculator
Estimate the value between ADCT shares and USD.
ADCT Shares to USD
1.00 ADCT shares = 1.525 USD
Calculations are estimates based on the latest available price and are for reference only.


